文献速递血栓与止血

预防性糖皮质激素联合valoctocogene roxaparvovec的安全性与疗效:3b期单臂开放标签GENEr8-3研究1年结果

Safety and efficacy of valoctocogene roxaparvovec with prophylactic glucocorticoids: 1-year results from the phase 3b, single-arm, open-label GENEr8-3 study.
PubMed 文献 · J Thromb Haemost · 2025-01-10

GENEr8-3研究纳入22例重型A型血友病患者,接受单次6×10^13 vg/kg valoctocogene roxaparvovec输注并同期预防性使用糖皮质激素。改良意向治疗人群(n=21)第52周FVIII活性较基线升高至16.1 IU/dL,治疗性年出血率和年FVIII用量分别较基线降低67.1%和91.6%。基于跨试验比较,预防性糖皮质激素相较反应性方案未带来安全性或疗效获益。

要点

  • 22例重型A型血友病患者接受单次6×10^13 vg/kg输注并同期预防性糖皮质激素。
  • 改良意向治疗人群第52周FVIII活性均值16.1 IU/dL,较基线1 IU/dL升高(P=.0057)。
  • 治疗性年出血率降低67.1%、年FVIII用量降低91.6%(P<.05)。

核心结论

  • 基于跨试验比较,预防性糖皮质激素相较反应性糖皮质激素方案未带来安全性或疗效获益。

研究设计与样本

  • 开放标签、单臂、3b期GENEr8-3试验,纳入正在使用A型血友病预防治疗的重型A型血友病患者。
  • 22例参与者接受单次6×10^13 vg/kg valoctocogene roxaparvovec输注,同期每日预防性糖皮质激素(第0-8周泼尼松龙等效40 mg/d,第9-19周逐渐减至5 mg/d)。
  • 安全性分析采用意向治疗人群(接受valoctocogene roxaparvovec者),疗效分析采用改良意向治疗人群(给药前一年内FVIII输注≥52次者,n=21)。

主要发现

  • 改良意向治疗人群(n=21)第52周FVIII活性(发色底物法)均值从基线(以1 IU/dL填补)增至16.1 IU/dL(SD 22.4;P=.0057)。
  • A型血友病预防治疗后,平均治疗性年出血率和平均年FVIII用量分别较基线降低67.1%和91.6%(P<.05)。
  • 最常见不良事件为丙氨酸氨基转移酶升高(20/22例参与者)。
  • 糖皮质激素相关不良事件发生于19/22例参与者。
  • 无参与者中止研究。

临床怎么用

  • 原文结论基于跨试验比较认为预防性糖皮质激素相较反应性方案未带来安全性或疗效获益,未据此给出推荐。

局限性

  • 原文结论基于跨试验比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Valoctocogene roxaparvovec, an adeno-associated virus vector that transfers a human factor (F)VIII (FVIII) coding sequence to hepatocytes, provides bleeding protection for people with severe hemophilia A. OBJECTIVES: Determine the efficacy and safety of valoctocogene roxaparvovec with concomitant prophylactic glucocorticoids in the open-label, single-arm, phase 3b GENEr8-3 trial. METHODS: Participants with severe hemophilia A who were using hemophilia A prophylaxis received one 6 × 1013 vg/kg infusion of valoctocogene roxaparvovec concomitantly with daily prophylactic glucocorticoids (40 mg prednisolone equivalent/d weeks 0-8; taper to 5 mg/d weeks 9-19). The primary efficacy endpoint was change from baseline in FVIII activity (chromogenic substrate assay) at week 52. Secondary efficacy endpoints included annualized rate of FVIII use and annualized bleeding rate for treated bleeds. Safety was assessed by adverse events (AEs). Analysis populations were intent-to-treat (ITT; received valoctocogene roxaparvovec) for safety analyses and modified ITT (≥52 FVIII infusions in the year before dosing) for efficacy analyses. RESULTS: Overall, 22 participants with severe hemophilia A received valoctocogene roxaparvovec. In the modified ITT population (n = 21), mean week 52 FVIII activity increased from baseline (imputed as 1 IU/dL) to 16.1 IU/dL (SD, 22.4; P = .0057); posthemophilia A prophylaxis, mean treated annualized bleeding rate and mean annualized FVIII use decreased 67.1% and 91.6% from baseline, respectively (P < .05). The most common AE was alanine aminotransferase elevation (20/22 participants). Glucocorticoid-related AEs occurred in 19 of 22 participants. No participants discontinued the study. CONCLUSION: Based on cross-trial comparisons, prophylactic glucocorticoids do not confer safety or efficacy benefits compared with reactive glucocorticoid regimens.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Ozelo MC, Mason J, Dunn AL, et al. Safety and efficacy of valoctocogene roxaparvovec with prophylactic glucocorticoids: 1-year results from the phase 3b, single-arm, open-label GENEr8-3 study. J Thromb Haemost. 2025. PMID: 39800255. doi:10.1016/j.jtha.2024.12.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。